To investigate the anticancer activity of the combination of metformin (MET) and parthenolide (PAR) against breast cancer in vitro and in vivo.
Key Findings:
MET and PAR exhibited a synergistic antiproliferative interaction against all tested breast cancer cell lines.
Combination therapy significantly reduced tumor size in vivo, with no treatment-related mortality.
The combination induced caspase-3-dependent apoptosis and reduced VEGF expression compared to either agent alone.
Serum levels of AST, ALT, and creatinine in combination-treated mice remained within normal ranges.
Interpretation:
The combination of MET and PAR demonstrates synergistic anticancer activity against breast cancer through mechanisms involving apoptosis induction and angiogenesis inhibition.
Limitations:
The study was conducted in animal models, which may not fully replicate human responses.
Further studies are needed for comprehensive molecular and mechanistic characterization.
Conclusion:
The combination of MET and PAR shows potential as a synergistic treatment for breast cancer.
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
